Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

Study Primary Objectives: To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral combination therapy with sulfonylurea and metformin. Study Secondary Objectives : To compare the following measures between subjects receiving insulin glargine or 75% insulin lispro protamine suspension/25% insulin lispro: * Incidence of hypoglycemia * Change in weight * Change in serum lipid profile * Percentage of subjects achieving A1C levels ≤7%

Key facts

Study ID

NCT01336751

Run by

Sanofi

People needed

212

Starts

2001-07-01

Expected to finish

2002-12-01

Last updated by the study team

2011-04-18

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have given their signed informed consent.
• Males or females between 18 and 79 years of age.
• Diagnosis of type 2 diabetes mellitus for at least one year.
• Patients must have had continuous oral hypoglycemic treatment for at least three months using dosing of: at least half maximally labeled dose of sulfonylurea + at least 1000 mg metformin daily.
• HBA1C ≥ 8 % and ≤11 %, inclusive, as measured at screening (visit 1).
• Patients must have BMI of > 25 kg/m2 at baseline
• Willingness to accept, and demonstrate ability to inject insulin glargine or 75% insulin lispro protamine suspension and 25% insulin lispro injection therapy.
• Ability and willingness to perform SMBG profiles using a plasma glucose meter at least twice a day.
• Patients must be able to understand and willing to adhere to and be compliant with the study protocol

You may not qualify if…

• Patients, who have had stroke, MI, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months.
• Patients with congestive heart failure requiring pharmacological treatment.
• Patients on non-selective beta blockers (including ocular).
• Patients with impaired renal function, as shown by but not limited to serum creatinine ≥ 1.5 mg/dl (133μmol/L) for males, or ≥ 1.4 mg/dl (124 μmol/L) for females.
• Patients with acute infections.
• Patients with diagnosis of dementia.
• Treatment with systemic steroids or large doses of inhaled steroids.
• Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Patients with planned radiological examinations requiring administration of contrasting agents.
• Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range.
• Patients with history of hypoglycemia unawareness.
• Pregnant or lactating females.
• Failure to use adequate contraception (women of current reproductive potential only).
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.